GlassScriptPhysician profile
David Gregory Mayernik
NPI 1083671846
$793.46
in general payments reported to CMS, 2019-2025
22 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $76.02 · 2023: $153 · 2024: $338 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $188.17 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $92.31 | 2023 | Myrisk |
| Sobi, INC | $68.18 | 2024 | |
| Daiichi Sankyo INC. | $48.29 | 2025 | Datroway, Vanflyta |
| Novartis Pharmaceuticals Corporation | $43.88 | 2024 | |
| Incyte Corporation | $41.19 | 2023-2024 | Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $27.68 | 2024 | Fruzaqla |
| Blueprint Medicines Corporation | $25.89 | 2023 | Ayvakit |
| Lilly USA, LLC | $25.30 | 2024 | Jaypirca, Retevmo, Verzenio |
| Astellas Pharma US INC | $24.33 | 2024 | Xtandi |
| Genzyme Corporation | $21.33 | 2023 | |
| Glaxosmithkline, LLC. | $21.12 | 2025 | Blenrep |
| Janssen Biotech, INC. | $20.87 | 2024 | Rybrevant |
| Syndax Pharmaceuticals, INC. | $18.14 | 2025 | Revuforj |
| Tempus Ai, INC | $17.80 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.75 | 2024 | |
| Tolmar, INC. | $17.17 | 2024 | |
| Exelixis INC. | $16.38 | 2024 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $15.80 | 2024 | Onivyde |
| Array Biopharma INC | $15.67 | 2024 | Tukysa, Mektovi, Braftovi |
| Rigel Pharmaceuticals, INC. | $15.17 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mayernik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.